- Home
- FMST vs APLM Comparison
FMST vs APLM Comparison
Compare FMST & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- APLM
- Stock Information
- Founded
- FMST 2005
- APLM 2016
- Country
- FMST Canada
- APLM United States
- Employees
- FMST N/A
- APLM N/A
- Industry
- FMST Other Metals and Minerals
- APLM Blank Checks
- Sector
- FMST Basic Materials
- APLM Finance
- Exchange
- FMST Nasdaq
- APLM Nasdaq
- Market Cap
- FMST 15.9M
- APLM 15.6M
- IPO Year
- FMST N/A
- APLM N/A
- Fundamental
- Price
- FMST $2.83
- APLM $0.16
- Analyst Decision
- FMST
- APLM Strong Buy
- Analyst Count
- FMST 0
- APLM 2
- Target Price
- FMST N/A
- APLM $4.25
- AVG Volume (30 Days)
- FMST 6.4K
- APLM 924.9K
- Earning Date
- FMST 01-01-0001
- APLM 08-14-2024
- Dividend Yield
- FMST N/A
- APLM N/A
- EPS Growth
- FMST N/A
- APLM N/A
- EPS
- FMST N/A
- APLM N/A
- Revenue
- FMST N/A
- APLM $2,101,000.00
- Revenue This Year
- FMST N/A
- APLM N/A
- Revenue Next Year
- FMST N/A
- APLM N/A
- P/E Ratio
- FMST N/A
- APLM N/A
- Revenue Growth
- FMST N/A
- APLM 70.54
- 52 Week Low
- FMST $1.77
- APLM $0.11
- 52 Week High
- FMST $4.25
- APLM $3.18
- Technical
- Relative Strength Index (RSI)
- FMST 42.92
- APLM 60.35
- Support Level
- FMST $2.65
- APLM $0.13
- Resistance Level
- FMST $2.95
- APLM $0.18
- Average True Range (ATR)
- FMST 0.21
- APLM 0.01
- MACD
- FMST -0.04
- APLM 0.00
- Stochastic Oscillator
- FMST 28.12
- APLM 65.52
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Lithium Resource & Technology Ltd is a hard-rock exploration company strategically located to capitalize on the growing EV appetite and is committed to being a supplier of North America's lithium feedstock. As the transition towards decarbonization, the company is focused on the exploration and growth of its five Lithium Lane Projects in Snow Lake Manitoba. It also has the Winston Gold/Silver Property in New Mexico, USA. The company mainly operates in one reportable operating segment being the acquisition and exploration of exploration and evaluation assets.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.